DoD Duchenne Muscular Dystrophy Translational Leverage Award | Apply Online

Opportunity Summary:

The DoD Duchenne Muscular Dystrophy Translational Leverage Award (TLA) was a FY2015 funding opportunity under the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP), administered by the U.S. Army Medical Research Acquisition Activity (USAMRAA). Introduced for the first time in FY15, the award was built around a practical idea: a lot of valuable human-based data and specimens already exist, but they often are not used to their full potential. When groups recreate the same kinds of datasets, cohorts, or sample collections, it wastes time and funding and slows progress. This mechanism aimed to speed translational research by paying investigators to "leverage" what is already available rather than starting from scratch, as long as the work directly addressed at least one FY15 DMDRP Focus Area and targeted high-impact questions or clear unmet needs in Duchenne muscular dystrophy (DMD).

The core purpose of the TLA was to support translational research that queries, mines, refines, or otherwise makes productive use of existing human-based resources such as repositories, registries, and data from clinical studies. The announcement makes clear that supported projects could span a range of translational activities, including drug and/or device development work that relies on existing human datasets, evaluation of novel interventions using previously collected human information, refinement or enhancement of existing resources so they become more informative or usable, database mining and advanced analyses of existing datasets, and correlative studies that connect biomarkers or other measures to clinical features or outcomes. A key expectation was that the work would not just produce a one-off result for a single lab. "Leveraging" in this program meant using existing resources to amplify knowledge gains for the broader DMD field and then making the resulting data or outcomes available for others to use. The intended payoff was actionable evidence and scientific rationale that could justify and shape subsequent research with a realistic path to improving DMD clinical care.

The opportunity emphasized "human-based resources," meaning materials and datasets that come from patients or patient-related clinical contexts. Examples listed in the announcement included biorepositories of clinical specimens, imaging repositories, epidemiological datasets, clinical databases, and broader databases containing clinical data and/or metadata. The structure of the award reflects a translational philosophy: human-derived data can help answer questions that are closer to patient care and can reduce the risk that findings will fail to translate from preclinical models to the clinic. The mechanism was designed to encourage investigators to connect existing human evidence to practical next steps, such as identifying promising therapeutic directions, clarifying disease trajectories, or sharpening tools used to measure treatment impact.

A specific area highlighted in the description was biomarker research, particularly projects aligned with the FY15 DMDRP focus area involving discovery and qualification of pharmacodynamic, prognostic, and predictive biomarkers. The announcement defines a biomarker as an objectively measured characteristic indicating normal biological processes, disease processes, or responses to a therapeutic intervention. It also draws an important distinction between qualification and validation. Biomarker qualification, as described, is a "fit for purpose" evidentiary process linking a biomarker to the effects of an agent on biological processes and clinical endpoints. Biomarker validation, in contrast, focuses on whether the biomarker or measurement technology can be accurately and reliably measured, including assay performance characteristics (and imaging technologies were explicitly mentioned as an example). The program encouraged biomarkers detectable through minimally invasive approaches such as blood, urine, tissue, or imaging, and it listed broad categories of potential biomarkers, including genetic or epigenetic signatures, gene expression patterns, proteins, metabolites, and molecular, physiological, or imaging measures. This emphasis fits the translational goal: better biomarkers can make it easier to track disease, stratify patients, predict outcomes, and evaluate therapeutic response more efficiently.

Even though the award allowed leveraging information from clinical trials or clinical studies, the mechanism explicitly did not support conducting clinical trials themselves. In other words, applicants could analyze or correlate existing trial or study data, but they could not use this award to run a new interventional trial. This boundary reinforces the program's intent to extract additional value from resources that already exist, producing analyses and datasets that can inform later studies and, potentially, future trials funded through other mechanisms.

From an administrative and funding standpoint, this opportunity was posted June 4, 2015, with an application closing date of October 21, 2015, and it was later archived on November 20, 2015. The funding opportunity number was W81XWH-15-DMDRP-TLA. The instrument type was listed as a cooperative agreement and grant within the Science and Technology and other Research and Development category. The estimated total funding was $400,000, with an expectation of one award, and there was no cost-sharing or matching requirement. Eligibility was described as unrestricted (open to any type of entity), subject to any additional clarifications in the full announcement text. The CFDA listing referenced was 12.420, Military Medical Research and Development, and applicants needing help accessing the full announcement were directed to the CDMRP Help Desk at 301-682-5507.

Overall, the Translational Leverage Award was designed as a targeted, efficiency-driven mechanism: use existing human-based DMD resources more intelligently, answer high-value translational questions aligned with program focus areas, and deliver outputs that the broader community can build on, with the ultimate goal of accelerating progress toward improvements in DMD clinical care without duplicating costly foundational resources.

Browse more opportunities from the same agency: Dept. of the Army USAMRAA

Browse more opportunities from the same category: Science and Technology and other Research and Development

Next opportunity: Musconetcong River Comprehensive Management Plan Implementation

Previous opportunity: DoD Duchenne Muscular Dystrophy Therapeutic Idea Award

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for W81XWH 15 DMDRP TLA

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (W81XWH 15 DMDRP TLA) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 15 DMDRP TLA", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.